Corrigendum to “Daidzein enhances efferocytosis via transglutaminase 2 and augmentation of Rac1 activity” [Mol. Immunol. 60 (2014) 135–142]

Yen, Jia Hau; Yang, Deng Jye; Chen, Meng Chi; Wu, Yi‐Ying; Hsieh, Yu Fan; Cheng, Yueh Mei; Huang, Wen Nan; Szondy, Zsuzsa; Tsay, Gregory J.

doi:10.1016/j.molimm.2014.07.001

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, multiple variants of TG2 have been identified, and the effects and impacts of this complex regulation remain to be clarified [ 68 ]. The involvement of TG2 in the efferocytosis of apoptotic cells [ 69 , 70 ] and in cross-linking during necrosis [ 71 ] suggests an important role in containing tissue damage and restricting potentially damaging inflammation as a result of cell death.…”

Section: Tg2 and The Hallmarks Of Cancermentioning

confidence: 99%

The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment

Tempest

Guarnerio

Maani

et al. 2021

Cancers

View full text Add to dashboard Cite

Transglutaminase-2 (TG2) is the most highly and ubiquitously expressed member of the transglutaminase enzyme family and is primarily involved in protein cross-linking. TG2 has been implicated in the development and progression of numerous cancers, with a direct role in multiple cellular processes and pathways linked to apoptosis, chemoresistance, epithelial-mesenchymal transition, and stem cell phenotype. The tumour microenvironment (TME) is critical in the formation, progression, and eventual metastasis of cancer, and increasing evidence points to a role for TG2 in matrix remodelling, modulation of biomechanical properties, cell adhesion, motility, and invasion. There is growing interest in targeting the TME therapeutically in response to advances in the understanding of its critical role in disease progression, and a number of approaches targeting biophysical properties and biomechanical signalling are beginning to show clinical promise. In this review we aim to highlight the wide array of processes in which TG2 influences the TME, focussing on its potential role in the dynamic tissue remodelling and biomechanical events increasingly linked to invasive and aggressive behaviour. Drug development efforts have yielded a range of TG2 inhibitors, and ongoing clinical trials may inform strategies for targeting the biomolecular and biomechanical function of TG2 in the TME.

show abstract